Investigation of Sacroiliac Fusion Treatment (INSITE)
NCT01681004
Degenerative Sacroiliitis, Sacroiliac Joint Disruption
La Jolla, California, United States
View Trial DetailsNCT Number: NCT01640353
The purpose of this study is to evaluate the use of the iFuse Implant System to treat degenerative sacroiliitis (arthritis of the SI joint) and sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint). The iFuse Implant System (iFuse device) is a medical device that is surgically implanted into the sacroiliac (SI) joint during a minimally invasive surgical procedure (one that uses a smaller incision and less damage to the skin and other tissues than standard surgery). The purpose of implanting the device is to stabilize and fuse the SI joint.
Looking for future studies?
Notify Me21 year–70 year
All sexes
Observational
Spine and Neuro Center, Huntsville, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i. SI joint disruption:
ii. Degenerative sacroiliitis:
Exclusion criteria
Time frame: Baseline and 6 months
Composite endpoint of reduction from baseline in VAS back pain score by at least 20 mm, lack of device-related serious adverse events, absence of neurologic worsening and absence of surgical re-intervention.
Time frame: 24 months
The Visual Analog Scale (VAS) is a 100 mm line on which the subject indicates their level of pain. 0 = no pain. 100 = worst imaginable pain.
Time frame: 24 months
Oswestry Disability Index is a validated patient questionnaire aiming to assess low back pain. The computed scores can be 0% to 100%. Lower scores indicate low disability while high scores indicate high disability. There are 10 questions on the questionnaire. Each has 6 possible answers (0 points - 5 points). If the question is skipped, it's points are subtracted from the denominator. If the raw score is 30 and all 10 questions were answered, the calculation would be 30 / 50 = 60%. If one question was skipped, it would be 30 / 45 = 67%.
Time frame: Baseline and 24 months
Change in QOL as measured by Short Form-36 PCS and EQ-5D at post-operative visits
Time frame: 24 months
Percentage of population fully ambulatory at 24 months post operatively.
Time frame: Basline, 24 months
Proportion of non-working subjects who return to work
Time frame: Procedure, discharge, 1,3,6,12,18 and 24 months
Occurrence of adverse events meeting the ISO14155:2011 definition of serious occurring during the procedure, at the time of hospital discharge (typically day of or next day after procedure), and at various times in late follow-up.
SI-BONE, Inc.
Industry
Acronym: SIFI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01681004
Degenerative Sacroiliitis, Sacroiliac Joint Disruption
La Jolla, California, United States
View Trial DetailsNCT07565545
Degenerative Sacroiliitis, Sacro Iliac Joint Pain
View Trial DetailsNCT04062630
Sacroiliac Joint Disruption, Scoliosis Lumbar Region
Phoenix, Arizona, United States
View Trial DetailsNCT02270203
Degenerative Sacroilitis, Sacroiliac Joint Disruption
New Haven, Connecticut, United States
View Trial Details